Pharmalot

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about AbbVie spending on doctors, a new Lilly deal, and more

Pharmalot Ed Silverman

STAT Plus: Biden administration appeals jury finding in battle over patents for HIV prevention pills

Pharmalot Ed Silverman

STAT Plus: U.K. trade group scolds Novo, Novartis, Pfizer, and Otsuka for violating industry codes

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Ozempic and an eye condition, a failed Roche cancer drug trial, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a GSK vaccine deal, an Alzheimer’s drug approval, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about FTC probing Teva patents, a Moderna flu vaccine contract, and more

Pharmalot Ed Silverman

STAT Plus: After months of warnings, FTC opens investigation into Teva over ‘improper’ patents

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about indicted drug wholesalers, a gene therapy rejection, and more

Pharmalot Ed Silverman

STAT Plus: Drug wholesaler owners indicted for alleged role in diverting Gilead and J&J HIV medicines

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about the Purdue bankruptcy ruling, a Merck rejection, and more

Pharmalot Ed Silverman

Supreme Court rejects the controversial Purdue bankruptcy plan

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about EMA plans for GLP-1 shortages, Walgreens store closings, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about rejection of an AbbVie Parkinson’s drug, PBM markups on mail order, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Novo’s Wegovy approval in China, a Merck KGaA cancer trial failure, and more

Pharmalot Ed Silverman

STAT Plus: U.K. pharma increasingly violates voluntary industry marketing codes, and probes are taking longer

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a plan for Medicare coverage of Wegovy, an Alnylam heart drug, and more

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about FDA approval for Sarepta drug, MSF closing access campaign and more

Pharmalot Ed Silverman

STAT Plus: Vertex reaches a new deal with NHS England over its pricey cystic fibrosis treatments

Exclusive Ed Silverman

STAT Plus: Doctors Without Borders is closing its widely regarded access-to-medicines campaign

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Lilly lawsuits, Novo Nordisk fires and much more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Merck pneumococcal shot, Kansas suing Pfizer, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an ‘unaffordable’ Novartis drug, a proposed patent rule, and more

Pharmalot Ed Silverman

STAT Plus: Under pressure to thwart pharma patent abuse, the PTO proposes a new rule. But will it fly?

Pharmalot Ed Silverman

STAT Plus: Colorado board decides a pricey Novartis medicine is unaffordable

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about abortion pill access, employer coverage of GLP-1 drugs and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Pfizer drug for Duchenne, bird flu vaccines for cows, and more